A simple blood test that can aid physicians in risk assessment and the early detection of lung cancer may significantly improve the prognosis for lung cancer patients.
The announcement of this medical breakthrough was made earlier this week by Oncimmune LLC, the maker of EarlyCDT-Lung™. Oncimmune reported that validation study results demonstrated the diagnostic and economic benefits of a standardized and reproducible autoantibody laboratory test (AABT).
EarlyCDT-Lung is priced below a CT (computed tomography) scan. As a simple blood test, it eliminates radiation exposure from imaging screening techniques. High-risk individuals, such as long-term smokers and ex-smokers between the ages of 40 and 75, are candidates for the test. People with other risk factors, such as environmental exposures and extensive exposure to secondary smoke, also are candidates for the test.
- Stabroek Newspapers
- Local Newspaper Kenya
- The Evening News Indiana
County news, sports, events, obituaries and classified ads.
- Nationalism News
Quinn DeBrock Chris Jefferson Connor Phares Oliver Cronk
- North Dakota Newspapers
